A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 687 participants.

Also called NCT03626688

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 687 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03626688
Other papers using this trial's data
  • Ralinepag for the treatment of pulmonary arterial hypertension (ADVANCE OUTCOMES): a randomised, double-blind, placebo-controlled phase 3 study Lancet (London, England), 2026-08-08 DOI, PubMed 42520828

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
United States, Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, China, Croatia, Czechia, Denmark, France, Germany, Greece, Hungary, Israel, Italy, Mexico, Netherlands, Poland, Portugal, Romania, Serbia, Singapore, South Korea, Spain, Sweden, Taiwan, Türkiye, Ukraine, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03626688. Randomized; quadruple masking; primary purpose treatment. Start 2019-01-24 (actual); primary completion 2025-12-31 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients
Condition
PAH
Condition
Pulmonary Arterial Hypertension
Condition
Hypertension
Condition
Connective Tissue Diseases
Condition
Familial Primary Pulmonary Hypertension
Condition
Vascular Diseases
Condition
Cardiovascular Diseases
Condition
Hypertension, Pulmonary
Condition
Lung Diseases
Condition
Respiratory Tract Disease
Intervention (Drug)
Ralinepag
Intervention (Drug)
Placebo
Lead sponsor
United Therapeutics (class: industry)

Record details

Record id
cardio:ct-nct03626688
Content hash
ba2c727294fe8b81976b0e7c76502b1fab440b9fe4ff2b35c41466cc10514746